KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) FCF Margin (2016 - 2025)

Historic FCF Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to 87.23%.

  • Ionis Pharmaceuticals' FCF Margin rose 54700.0% to 87.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.17%, marking a year-over-year increase of 80200.0%. This contributed to the annual value of 77.46% for FY2024, which is 354000.0% down from last year.
  • Ionis Pharmaceuticals' FCF Margin amounted to 87.23% in Q3 2025, which was up 54700.0% from 50.01% recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year FCF Margin high stood at 50.01% for Q2 2025, and its period low was 134.53% during Q4 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' median FCF Margin value was 55.99% (recorded in 2024), while the average stood at 54.37%.
  • In the last 5 years, Ionis Pharmaceuticals' FCF Margin surged by 3568300bps in 2021 and then plummeted by -1802500bps in 2022.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' FCF Margin stood at 45.72% in 2021, then plummeted by -394bps to 134.53% in 2022, then surged by 108bps to 10.38% in 2023, then tumbled by -702bps to 62.51% in 2024, then crashed by -40bps to 87.23% in 2025.
  • Its FCF Margin was 87.23% in Q3 2025, compared to 50.01% in Q2 2025 and 124.12% in Q1 2025.